sprint what remains unanswered? where do we go from here? embargoed until 2 p.m. et, monday, nov. 9,...
TRANSCRIPT
![Page 1: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/1.jpg)
SPRINTWhat Remains Unanswered?
Where Do We Go From Here?
Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015
![Page 2: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/2.jpg)
SPRINT
How generalizable are the results?
![Page 3: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/3.jpg)
SPRINT
![Page 4: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/4.jpg)
SPRINT
How generalizable are the results?
How is the J Curve relationship impacted by:
•Elevated Blood Pressure?•Age?•Cardiovascular and Cerebrovascular Disease?•Chronic Kidney Disease?•Diabetes Mellitus?
![Page 5: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/5.jpg)
SPRINT
Unanswered questions in need of further studies:
•What is the optimal SBP goal for patients with DM?
• Did ACCORD answer this?
![Page 6: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/6.jpg)
SPRINT
If the ACCORD results and interpretation are correct…
•Is the difference in SPRINT and ACCORD results due to the impact of DM on vasculature?
![Page 7: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/7.jpg)
SPRINT
Diabetes impact on vasculature?
• Is DM negatively impacting arteriolar autoregulation in the renal vasculature?
• Is this shifting the J curve relationship in patients with DM and HTN?
![Page 8: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/8.jpg)
SPRINT
![Page 9: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/9.jpg)
SPRINT
![Page 10: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/10.jpg)
SPRINT
Why different outcomes in SPRINT and ACCORD?
![Page 11: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/11.jpg)
SPRINT
Why different outcomes in SPRINT and ACCORD?
•Was ACCORD underpowered?• Young population• Lower risk because of lipid arm• Excluded patients with Cr > 1.5
![Page 12: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/12.jpg)
SPRINT
Why different outcomes in SPRINT and ACCORD?
•Was ACCORD underpowered?• Young population• Lower risk because of lipid arm• Excluded patients with Cr > 1.5
•Difference in diuretic use?• ACCORD often used HCTZ• SPRINT primarily used Chlorthalidone
![Page 13: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/13.jpg)
SPRINT
Why different outcomes in SPRINT and ACCORD?
•Was ACCORD underpowered?• Young population• Lower risk because of lipid arm• Excluded patients with Cr > 1.5
•Difference in diuretic use?• ACCORD often used HCTZ• SPRINT primarily used Chlorthalidone
•Trial Design Complex for ACCORD
![Page 14: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/14.jpg)
SPRINT
Important related questions for diabetes mellitus:
•Should another trial in DM be done assuring adequate power?
•What SBP goal should the new ACC/AHA guidelines recommend for diabetics?• Should this be 140, 135, 130, or 120?• Recommendation will be based on expert
opinion• Adverse events in ACCORD were few
![Page 15: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/15.jpg)
SPRINT
Unanswered questions in need of further trials:
•Heart failure with low ejection fraction
•Heart failure with preserved ejection fraction
•Drug therapy for untreated SBP 120-140?• No benefit in previous trials in patients at this
risk level?• Or were there power issues with these trials as
well?
![Page 16: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/16.jpg)
SPRINT
Unanswered questions in HTN unrelated to goal SBP:
•Will we discover meaningful ways to prevent and treat obesity?
•Will precision medicine offer opportunities to refine optimal BP management?• Goal SBP for individuals • More narrowly defined groups
![Page 17: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/17.jpg)
SPRINT
Where do we go from here?
•Consider SPRINT results in new ACC/AHA Blood Pressure Management Guidelines• Goal SBP for various groups including DM and
lower risk patients including < 50 • Management of SBP 120-140• Consider Global CV Risk?• Classification of blood pressure?
![Page 18: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/18.jpg)
SPRINT
Where do we go from here?
• Continue and increase efforts in hypertension research• basic science• translational science• clinical trials• population science
•BP measurement research•BP components research•Test lower goals in younger patients
![Page 19: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/19.jpg)
SPRINT
Where do we go from here?
•Continue and increase efforts in related research • Obesity• Precision medicine
•Continue efforts to better implement what we know • lifestyle approaches • focus on early prevention• improvement of the environment
![Page 20: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/20.jpg)
SPRINT
Where do we go from here?
Pause momentarily to appreciate the progress in the field of hypertension including the positive results of SPRINT
![Page 21: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/21.jpg)
SPRINT
Acknowledgements
•John Hall•Marion Wofford•Lyssa Weatherly•Bill Cushman•Paul Whelton
![Page 22: SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfd31a28abf838cac6a2/html5/thumbnails/22.jpg)
SPRINT
THANK YOU